{"transactions":[{"id":4636034,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40088,"kind":"person","name":"Posner Brian S","position":1,"cik":"0001372455","reported_name":"Posner Brian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T20:15:03.000Z","date":"2026-10-02","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":16,"value":40000.0,"ownership":{"direct":true},"balance_after":27000,"source":{"system":"sec-edgar","filing":"0001193125-26-415584","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526415584/ownership.xml","form_type":"4"}},{"id":3518151,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:15:26.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":185,"price":18.88,"value":3492.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 102,966 unvested RSUs."}],"balance_after":152897,"source":{"system":"sec-edgar","filing":"0001915598-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000005/ownership.xml","form_type":"4"}},{"id":3518150,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:15:26.000Z","date":"2026-09-04","kind":"sale","planned":true,"acquired":false,"shares":900,"price":24.35,"value":21915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.29 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":153082,"source":{"system":"sec-edgar","filing":"0001915598-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000005/ownership.xml","form_type":"4"}},{"id":3517710,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22908,"kind":"person","name":"Kerr Douglas","position":1,"cik":"0001814189","reported_name":"Kerr Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:14:26.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":1290,"price":18.88,"value":24355.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 125,126 unvested RSUs."}],"balance_after":162564,"source":{"system":"sec-edgar","filing":"0001814189-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000181418926000005/ownership.xml","form_type":"4"}},{"id":3517709,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22908,"kind":"person","name":"Kerr Douglas","position":1,"cik":"0001814189","reported_name":"Kerr Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:14:26.000Z","date":"2026-09-04","kind":"sale","planned":true,"acquired":false,"shares":3745,"price":24.35,"value":91190.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.27 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":163854,"source":{"system":"sec-edgar","filing":"0001814189-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000181418926000005/ownership.xml","form_type":"4"}},{"id":3517314,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-09-08T20:13:46.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":5658,"price":18.88,"value":106823.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 239,233 unvested RSUs."}],"balance_after":357507,"source":{"system":"sec-edgar","filing":"0001498428-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000149842826000005/ownership.xml","form_type":"4"}},{"id":685632,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":322465,"price":25,"value":8061625.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":428946,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685631,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":478377,"price":25,"value":11959425.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":567358,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685630,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-14","kind":"sale","planned":true,"acquired":false,"shares":1359674,"price":25,"value":33991850.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2441454,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685629,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":63643,"price":26.2,"value":1667446.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":751411,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685628,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":94415,"price":26.2,"value":2473673.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1045735,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":685627,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-17T21:30:08.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":268354,"price":26.2,"value":7030874.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":3801128,"source":{"system":"sec-edgar","filing":"0001577014-26-000016","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000016/form4-08172026_050803.xml","form_type":"4"}},{"id":686095,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-08-17T20:08:51.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":226,"price":26.28,"value":5939.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 119,928 unvested RSUs."}],"balance_after":153982,"source":{"system":"sec-edgar","filing":"0001915598-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000004/ownership.xml","form_type":"4"}},{"id":685626,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22908,"kind":"person","name":"Kerr Douglas","position":1,"cik":"0001814189","reported_name":"Kerr Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-17T20:08:07.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":1556,"price":26.28,"value":40891.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 140,001 unvested RSUs."}],"balance_after":167599,"source":{"system":"sec-edgar","filing":"0001814189-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000181418926000004/ownership.xml","form_type":"4"}},{"id":685625,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-08-17T20:07:22.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":4986,"price":26.28,"value":131032.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 248,314 unvested RSUs."}],"balance_after":363165,"source":{"system":"sec-edgar","filing":"0001498428-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000149842826000004/ownership.xml","form_type":"4"}},{"id":685623,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22905,"kind":"person","name":"Lucera Erick","position":1,"cik":"0001697616","reported_name":"Lucera Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-17T20:06:18.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":1797,"price":26.28,"value":47225.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 106,451 unvested RSUs."}],"balance_after":119766,"source":{"system":"sec-edgar","filing":"0001697616-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000169761626000002/ownership.xml","form_type":"4"}},{"id":701493,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T20:15:04.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":5388,"price":26.0428,"value":140318.6064,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3586796,"source":{"system":"sec-edgar","filing":"0001193125-26-323754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526323754/ownership.xml","form_type":"4"}},{"id":701492,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T20:15:04.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":256072,"price":25.5024,"value":6530450.5728,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3592184,"source":{"system":"sec-edgar","filing":"0001193125-26-323754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526323754/ownership.xml","form_type":"4"}},{"id":712696,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":23.61,"value":118050.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.50 to $23.794 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2962,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712695,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":11665,"price":23.62,"value":275527.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":815054,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712694,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":49193,"price":23.17,"value":1139801.81,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":826719,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712693,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":14844,"price":23.62,"value":350615.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1140150,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712692,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":62543,"price":23.17,"value":1449121.31,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1154994,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712691,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":29587,"price":23.62,"value":698844.94,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4069482,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712690,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":124379,"price":23.17,"value":2881861.43,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4099069,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712689,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":100019,"price":22.79,"value":2279433.01,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":875912,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712688,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":127182,"price":22.79,"value":2898477.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1217537,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":712687,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:35:11.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":253039,"price":22.79,"value":5766758.81,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4223448,"source":{"system":"sec-edgar","filing":"0001577014-26-000014","document":"form4-07082026_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000014/form4-07082026_090708.xml","form_type":"4"}},{"id":722899,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":40702,"price":21.14,"value":860440.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":975931,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722898,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":51756,"price":21.14,"value":1094121.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1344719,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722897,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":102969,"price":21.14,"value":2176764.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.3247 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4476487,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722896,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":64411,"price":21.28,"value":1370666.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1016633,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722895,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":81903,"price":21.28,"value":1742895.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1396475,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":722894,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T23:05:14.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":162954,"price":21.28,"value":3467661.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.61 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4579456,"source":{"system":"sec-edgar","filing":"0001577014-26-000012","document":"form4-06302026_110610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000012/form4-06302026_110610.xml","form_type":"4"}},{"id":725575,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22905,"kind":"person","name":"Lucera Erick","position":1,"cik":"0001697616","reported_name":"Lucera Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T20:15:07.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":2362,"price":20.37,"value":48113.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.33 to $20.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 110,513 unvested RSUs."}],"balance_after":121563,"source":{"system":"sec-edgar","filing":"0001193125-26-285505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526285505/ownership.xml","form_type":"4"}},{"id":725573,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":5019,"price":21.1,"value":105900.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1081044,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725572,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":6382,"price":21.1,"value":134660.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1478378,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725571,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":12699,"price":21.1,"value":267948.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4742410,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725570,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":19973,"price":21.02,"value":419832.46,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1086063,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725569,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":25397,"price":21.02,"value":533844.94,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1484760,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725568,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":50530,"price":21.02,"value":1062140.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4755109,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725567,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":30774,"price":21.13,"value":650254.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1106036,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725566,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":39131,"price":21.13,"value":826838.03,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1510157,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":725565,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T12:40:23.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":77855,"price":21.13,"value":1645076.15,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4805639,"source":{"system":"sec-edgar","filing":"0001577014-26-000010","document":"form4-06262026_120619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000010/form4-06262026_120619.xml","form_type":"4"}},{"id":727770,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:27:26.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":1657,"price":21.4742,"value":35582.7494,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.45 to $21.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3848256,"source":{"system":"sec-edgar","filing":"0001193125-26-281119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526281119/ownership.xml","form_type":"4"}},{"id":727769,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:27:26.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":71629,"price":21.0357,"value":1506766.1553,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.45 to $21.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3849913,"source":{"system":"sec-edgar","filing":"0001193125-26-281119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526281119/ownership.xml","form_type":"4"}},{"id":727768,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:27:26.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":190676,"price":20.5703,"value":3922262.5228,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.13 to $20.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3921542,"source":{"system":"sec-edgar","filing":"0001193125-26-281119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526281119/ownership.xml","form_type":"4"}},{"id":729233,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-23T20:07:02.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":57463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029."}],"balance_after":57463,"derivative":{"exercise_price":20.87,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":57463},"source":{"system":"sec-edgar","filing":"0001291963-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000129196326000008/ownership.xml","form_type":"4"}},{"id":730628,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:15:03.000Z","date":"2026-06-18","kind":"sale","planned":true,"acquired":false,"shares":46901,"price":20.0715,"value":941373.4215,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4112218,"source":{"system":"sec-edgar","filing":"0001193125-26-277529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526277529/ownership.xml","form_type":"4"}},{"id":730627,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:15:03.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":37454,"price":20.1398,"value":754316.0692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4159119,"source":{"system":"sec-edgar","filing":"0001193125-26-277529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526277529/ownership.xml","form_type":"4"}},{"id":734253,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22908,"kind":"person","name":"Kerr Douglas","position":1,"cik":"0001814189","reported_name":"Kerr Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-17T20:08:45.000Z","date":"2026-06-16","kind":"sale","planned":true,"acquired":false,"shares":887,"price":18.33,"value":16258.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 145,313 unvested RSUs."}],"balance_after":169155,"source":{"system":"sec-edgar","filing":"0001814189-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000181418926000002/ownership.xml","form_type":"4"}},{"id":735076,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-17T20:07:50.000Z","date":"2026-06-16","kind":"sale","planned":true,"acquired":false,"shares":145,"price":18.33,"value":2657.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.01 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 123,678 unvested RSUs."}],"balance_after":154208,"source":{"system":"sec-edgar","filing":"0001915598-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000002/ownership.xml","form_type":"4"}},{"id":734254,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-06-17T20:07:11.000Z","date":"2026-06-16","kind":"sale","planned":true,"acquired":false,"shares":2683,"price":18.33,"value":49179.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 259,564 unvested RSUs."}],"balance_after":368151,"source":{"system":"sec-edgar","filing":"0001498428-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000149842826000002/ownership.xml","form_type":"4"}},{"id":744762,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:15:59.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264031/ownership.xml","form_type":"4"}},{"id":744761,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:13:55.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264025","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264025/ownership.xml","form_type":"4"}},{"id":744760,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:13:25.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264022","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264022/ownership.xml","form_type":"4"}},{"id":744759,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:12:56.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264021/ownership.xml","form_type":"4"}},{"id":744758,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40091,"kind":"person","name":"Incerti Carlo","position":1,"cik":"0001915358","reported_name":"Incerti Carlo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:12:25.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264019","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264019/ownership.xml","form_type":"4"}},{"id":744757,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40090,"kind":"person","name":"Stehman-Breen Catherine","position":1,"cik":"0001702233","reported_name":"Stehman-Breen Catherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:09:25.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264011","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264011/ownership.xml","form_type":"4"}},{"id":744755,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40088,"kind":"person","name":"Posner Brian S","position":1,"cik":"0001372455","reported_name":"Posner Brian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:06:18.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264004/ownership.xml","form_type":"4"}},{"id":744754,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40088,"kind":"person","name":"Posner Brian S","position":1,"cik":"0001372455","reported_name":"Posner Brian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T21:06:18.000Z","date":"2026-06-08","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":16.94,"value":33880.0,"ownership":{"direct":true},"balance_after":24500,"source":{"system":"sec-edgar","filing":"0001193125-26-264004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264004/ownership.xml","form_type":"4"}},{"id":748146,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40088,"kind":"person","name":"Posner Brian S","position":1,"cik":"0001372455","reported_name":"Posner Brian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:10:04.000Z","date":"2026-06-03","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":17.48,"value":43700.0,"ownership":{"direct":true},"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001193125-26-259563","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526259563/ownership.xml","form_type":"4"}},{"id":760292,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40088,"kind":"person","name":"Posner Brian S","position":1,"cik":"0001372455","reported_name":"Posner Brian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:11:20.000Z","date":"2026-05-26","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":18.21,"value":36420.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001193125-26-245237","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526245237/ownership.xml","form_type":"4"}},{"id":766101,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40088,"kind":"person","name":"Posner Brian S","position":1,"cik":"0001372455","reported_name":"Posner Brian S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:10:03.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":17.12,"value":42800.0,"ownership":{"direct":true},"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001193125-26-236877","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526236877/ownership.xml","form_type":"4"}},{"id":779836,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-05-14T20:05:18.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":228,"price":18.36,"value":4186.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 126,040 unvested RSUs."}],"balance_after":154353,"source":{"system":"sec-edgar","filing":"0001193125-26-223984","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000119312526223984/ownership.xml","form_type":"4"}},{"id":779358,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22908,"kind":"person","name":"Kerr Douglas","position":1,"cik":"0001814189","reported_name":"Kerr Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-14T20:04:28.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":1564,"price":18.36,"value":28715.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 148,313 unvested RSUs."}],"balance_after":170042,"source":{"system":"sec-edgar","filing":"0001193125-26-223966","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526223966/ownership.xml","form_type":"4"}},{"id":779359,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22905,"kind":"person","name":"Lucera Erick","position":1,"cik":"0001697616","reported_name":"Lucera Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-14T20:03:26.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":1448,"price":18.36,"value":26585.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 110,513 unvested RSUs."}],"balance_after":123925,"source":{"system":"sec-edgar","filing":"0001193125-26-223961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526223961/ownership.xml","form_type":"4"}},{"id":779356,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-05-14T20:02:42.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":3311,"price":18.36,"value":60789.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 268,645 unvested RSUs."}],"balance_after":370834,"source":{"system":"sec-edgar","filing":"0001193125-26-223955","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526223955/ownership.xml","form_type":"4"}},{"id":790022,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":17244,"price":18.18,"value":313495.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1136810,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790021,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":428,"price":18.18,"value":7781.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":7962,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790020,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":43621,"price":18.18,"value":793029.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4883494,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790019,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":21926,"price":18.18,"value":398614.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1549288,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790018,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":2403,"price":18.03,"value":43326.09,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1154054,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790017,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":60,"price":18.03,"value":1081.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8390,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790016,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":6081,"price":18.03,"value":109640.43,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4927115,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790015,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":3056,"price":18.03,"value":55099.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1571214,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790014,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":2466,"price":18,"value":44388.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1156457,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790013,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":61,"price":18,"value":1098.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8450,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790012,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":6241,"price":18,"value":112338.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4933196,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":790011,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T21:09:41.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":3136,"price":18,"value":56448.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1574270,"source":{"system":"sec-edgar","filing":"0001577014-26-000008","document":"form4-05062026_090534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000008/form4-05062026_090534.xml","form_type":"4"}},{"id":796967,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":21,"price":19,"value":399.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1158923,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796966,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":1,"price":19,"value":19.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8511,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796965,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":52,"price":19,"value":988.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4939437,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796964,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":26,"price":19,"value":494.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1577406,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796963,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":47082,"price":18.38,"value":865367.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1158944,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796962,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":1170,"price":18.38,"value":21504.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":8512,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796961,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":119115,"price":18.38,"value":2189333.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4939489,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":796960,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-30T21:22:11.000Z","date":"2026-04-28","kind":"sale","planned":true,"acquired":false,"shares":59870,"price":18.38,"value":1100410.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1577432,"source":{"system":"sec-edgar","filing":"0001577014-26-000006","document":"form4-04302026_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000006/form4-04302026_090407.xml","form_type":"4"}},{"id":798895,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-28T20:56:31.000Z","date":"2026-04-24","kind":"gift","planned":false,"acquired":false,"shares":53625,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-187601","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526187601/ownership.xml","form_type":"4"}},{"id":800097,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":35947,"price":18.15,"value":652438.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1206026,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800096,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":894,"price":18.15,"value":16226.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":9682,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800095,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":90943,"price":18.15,"value":1650615.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5058604,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800094,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-27","kind":"sale","planned":true,"acquired":false,"shares":45709,"price":18.15,"value":829618.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1637302,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800093,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":28583,"price":18.48,"value":528213.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1241973,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800092,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":710,"price":18.48,"value":13120.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":10576,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800091,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":72310,"price":18.48,"value":1336288.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5149547,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800090,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-24","kind":"sale","planned":true,"acquired":false,"shares":36345,"price":18.48,"value":671655.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. (\"AVOF II\"). Atlas Venture Associates Opportunity II, LP (\"AVAO II LP\") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC (\"AVAO II LLC\") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1683011,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800089,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":15148,"price":19.19,"value":290690.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF I\"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. (\"AVAO I LP\"). Atlas Venture Associates Opportunity I, LLC (\"AVAO I LLC\") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1270556,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800088,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":377,"price":19.19,"value":7234.63,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any."}],"balance_after":11286,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}},{"id":800087,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22909,"kind":"person","name":"Rhodes Jason P","position":1,"cik":"0001577014","reported_name":"Rhodes Jason P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T22:15:33.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":38322,"price":19.19,"value":735399.18,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Atlas Venture Fund XI, L.P. (\"Atlas Venture Fund XI\"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. (\"AVA XI LP\"). Atlas Venture Associates XI, LLC (\"AVA XI LLC\") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any."}],"balance_after":5221857,"source":{"system":"sec-edgar","filing":"0001577014-26-000004","document":"form4-04272026_100429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000157701426000004/form4-04272026_100429.xml","form_type":"4"}}],"next_cursor":"2026-04-27T22:15:33.000000Z,800087"}